Login
Communauté Vinci
Extérieur
Si votre nom d'utilisateur ne se termine pas par @vinci.be ou @student.vinci.be, utilisez le formulaire ci-dessous pour accéder à votre compte de lecteur.
Titre : | Botulinum Toxin Treatment for Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial (2017) |
Auteurs : | Sang Jun Park ; Kyung Bong Yoon ; Duck Mi Yoon |
Type de document : | Article |
Dans : | Archives of Physical Medicine and Rehabilitation (2017/5, 2017) |
Article en page(s) : | pp. 957-963 |
Langues: | Anglais |
Descripteurs : |
HE Vinci Rééducation et réadaptation |
Mots-clés: | Botulinum toxins ; Toxines botuliniques ; Muscle cramp ; Crampe musculaire ; Spinal stenosis ; Sténose du canal vertébral |
Résumé : |
Objectives To evaluate the clinical effectiveness of botulinum toxin (BTX) injection into the gastrocnemius muscles in patients with lumbar spinal stenosis (LSS) who have frequent nocturnal calf cramps (NCCs). Design Prospective, randomized clinical trial. Setting Outpatient department for interventional pain management. Participants Patients (N=50) with LSS who have NCCs at least once per week were enrolled. Intervention Patients were randomly allocated to receive either conservative treatments plus gabapentin (group GPN) or BTX injection (group BTX). Main Outcome Measures We assessed back/leg pain intensity, the frequency and severity of NCCs, insomnia severity, and functional disability at baseline and after 2 weeks, 1 month, and 3 months. Additionally, Patient Global Impression of Change was assessed. Results Forty-five patients completed all assessments (group GPN, n=21; group BTX, n=24). Compared with group GPN, leg pain intensity, cramp frequency, and cramp severity were significantly decreased in group BTX at all follow-up visits (all, P<.01 also insomnia significantly improved in group btx at the and follow-up functional disability weeks patients reported a higher impression of improvement for ncc symptoms than did those gpn mean dose gabapentin was given daily but systemic side effects. there were no serious complications related to use.> Conclusions BTX treatment appears to be effective and safe for NCCs in symptomatic LSS patients receiving conservative care. |
Disponible en ligne : | Oui |
En ligne : | https://login.ezproxy.vinci.be/login?url=https://www.sciencedirect.com/science/article/pii/S0003999317300825 |